Pfizer made a deal with the White House to avoid paying tariffs on imported products.
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 05 Oct 2025, 18:45 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
This video presents a fundamental analysis of Pfizer stock, ticker PFE. The analyst begins by noting that pharmaceutical stocks, specifically PFE, have had some positive news, due to a deal with the current US administration alleviating risks for investors. He mentions his year-long buy rating on PFE and other pharmaceuticals including Novo Nordisk and Eli Lilly. He points out the recent rise in pharmaceutical stock prices, fueled by an agreement where Pfizer will slash drug prices for Americans enrolled in Medicaid in exchange for a three-year reprieve on import tariffs. Pfizer also agreed to invest $70 billion in the US under an agreement with President Donald Trump. The analyst discusses the frequent changes in tariff policy under the current administration and the intrinsic value per share that he calculates for PFE at $75.25, noting that the current market price, is below the share's intrinsic value. The video concludes with the analyst reiterating a buy rating on Pfizer for long-term investors, acknowledging the high risks currently involved but the potential of the company.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.